CG
ONCT

Cutler Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Cutler Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-103
Closed -$1K – 4763
2018
Q3 		$1K Buy
103
+93
+930% +$223K ﹤0.01% 3929
2018
Q2 		$1K Buy
+10
New +$25.4K ﹤0.01% 4020

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's ONCT Position: Q1 2019 in Review

Cutler Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 12 shares — an estimated $1K sold.

Cutler Group first reported a position in ONCT in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q3 2018. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

  • Cutler Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 12 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $1K.
  • Cutler Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Cutler Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.